Chevy Chase Trust Holdings LLC Has $73.89 Million Stake in Pfizer Inc. $PFE

Key Points

• Chevy Chase Trust Holdings LLC has increased its stake in Pfizer Inc. by 0.9%, holding approximately 3 million shares valued at $73.89 million as of the end of the last quarter.
• Analysts have mixed opinions on Pfizer, with some firms upgrading price targets while others have downgraded ratings; the stock maintains a consensus rating of "Hold" and an average price target of $28.13.
• Pfizer has announced a quarterly dividend of $0.43 per share, representing an annualized yield of 7.1%, which will be paid to stockholders on December 1st.

Chevy Chase Trust Holdings LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 0.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,048,329 shares of the biopharmaceutical company's stock after buying an additional 26,913 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of Pfizer worth $73,891,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Capital Advisory Group Advisory Services LLC grew its position in Pfizer by 2.9% in the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after purchasing an additional 388 shares during the period. Citizens National Bank Trust Department grew its position in Pfizer by 0.9% in the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company's stock valued at $1,118,000 after purchasing an additional 395 shares during the period. Trust Co of the South grew its position in Pfizer by 1.5% in the 2nd quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC grew its position in Pfizer by 4.3% in the 2nd quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after purchasing an additional 444 shares during the period. Finally, Ballentine Partners LLC grew its position in Pfizer by 0.5% in the 2nd quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock valued at $2,260,000 after purchasing an additional 458 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley cut their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.13.

Pfizer Trading Down 0.7%

NYSE PFE opened at $24.22 on Friday. The stock has a market capitalization of $137.70 billion, a price-to-earnings ratio of 12.88, a PEG ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.53. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business's fifty day moving average is $24.89 and its 200-day moving average is $24.12.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. The ex-dividend date is Friday, November 7th. Pfizer's payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.